
Microbiome Market Report 2026
Global Outlook – By Microbe Category (Bacteria, Archaea, Viruses, Other Microbiomes), By Product (Therapeutics, Diagnostics), By Technology (Genomics, Proteomics, Metabolomics), By End-Use (Infectious Diseases, Gastrointestinal Disorders, Metabolic Disorders, Cancers, Other Diseases) – Market Size, Trends, Strategies, and Forecast to 2035
Microbiome Market Overview
• microbiomes-global-market-report" target="_blank">microbiome market size has reached to $0.82 billion in 2025 • Expected to grow to $1.64 billion in 2030 at a compound annual growth rate (CAGR) of 15% • Growth Driver: The Role Of Rising Healthcare Expenditure In Fueling The Microbiome Market • Market Trend: Innovative Personalized Health Insights To Enhance Preventive Healthcare • North America was the largest region in 2025.What Is Covered Under Microbiome Market?
Microbiome refers to a group of microbes that live in a certain habitat and include fungi, bacteria, and viruses. It is all of the bacteria, fungi, protozoa, and viruses' genetic material that dwells on and within the human body. The microbiome's bacteria also aid in digestion, immune system control, defense against disease-causing bacteria, and the production of vitamins like Vitamin K, which is required for blood clotting, and the B vitamins B12, thiamine, and riboflavin. The main types of microbiomes are bacteria, archaea, viruses, and other microbiomes. Bacteria are single-celled microorganisms that belong to the domain Bacteria. They are among the most diverse and abundant life forms on Earth, existing in a wide range of environments. The various products used in microbiomes are therapeutics and diagnostics. The different technologies include genomics, proteomics, and metabolomics and are used in inflammatory bowel disease, gastrointestinal disorders, metabolic disorders, cancers, and other diseases.
What Is The Microbiome Market Size and Share 2026?
The microbiome market size has grown rapidly in recent years. It will grow from $0.82 billion in 2025 to $0.94 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to rising awareness about gut health, increased research funding in microbiome studies, growth in probiotic consumption, advances in sequencing technologies, partnerships between research institutions and biotech firms.What Is The Microbiome Market Growth Forecast?
The microbiome market size is expected to see rapid growth in the next few years. It will grow to $1.64 billion in 2030 at a compound annual growth rate (CAGR) of 15.0%. The growth in the forecast period can be attributed to integration of ai in microbiome analysis, personalized medicine adoption, expansion of microbiome-based therapeutics, rise in chronic disease prevalence, increasing demand for functional foods and supplements. Major trends in the forecast period include personalized microbiome-based therapies, probiotic and prebiotic innovation, microbiome diagnostic development, gut-brain axis research expansion, microbiome data integration and analysis.Global Microbiome Market Segmentation
1) By Microbe Category: Bacteria, Archaea, Viruses, Other Microbiomes 2) By Product: Therapeutics, Diagnostics 3) By Technology: Genomics, Proteomics, Metabolomics 4) By End-Use: Infectious Diseases, Gastrointestinal Disorders, Metabolic Disorders, Cancers, Other Diseases Subsegments: 1) By Bacteria: Probiotic Bacteria, Pathogenic Bacteria, Environmental Bacteria, Bacterial Communities In Various Ecosystems 2) By Archaea: Methanogens, Halophiles, Acidophiles, Other Extremophiles 3) By Viruses: Bacteriophages, Eukaryotic Viruses, Environmental Viruses 4) By Other Microbiomes: Fungi, Protists, Helminths, MycobiomeWhat Is The Driver Of The Microbiome Market?
The rising healthcare expenditure is expected to propel the growth of the microbiome market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare services and related goods and activities within a specific healthcare system or economy over a defined period. Healthcare expenditures play a pivotal role in boosting the microbiome market. As investments in microbiome research and development increase, along with heightened awareness regarding the microbiome's significance in human health, there is a growing demand for microbiome-based therapies and products. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, rising healthcare expenditures are driving the growth of the complicated skin and skin structure infections drugs market.Key Players In The Global Microbiome Market
Major companies operating in the microbiome market are Seres Therapeutics, Enterome Bioscience, Ferring Pharmaceuticals, Vedanta BioSciences, Second Genome Inc., Microbiotica, Rebiotix Inc, Locus Biosciences, Osel Inc., Xbiome Co. Ltd, Microba Life Sciences, Biome Australia, Shoreline Biome, BugSpeaks, Atlas Biomed, BiomX Ltd, ImmuneBiotech Medical Sweden AB, MetaboGen AB, Viome, PharmaBiome, NCCR Microbiomes, MaaT Pharma, Eligo Bioscience, T3 Pharmaceuticals, MicroBiome Therapeutics LLC, OpenBiome, Microbiome Insights Inc., Lallemand Health Solutions, Mybiotics Pharma, DayTwo, Next Biosciences, ViThera Pharmaceuticals Inc., Inqaba Biotechnical Industries (Pty), SNIPR Biome, MyBiomeGlobal Microbiome Market Trends and Insights
Major companies operating in the microbiome market are focusing on developing innovation, such as personalized health insights that aim to empower individuals by delivering tailored reports that highlight specific health concerns. Personalized health insights refer to customized, data-driven information and recommendations tailored to an individual's unique health profile. For instance, in September 2024, Redcliffe Labs, an India-based medical and diagnostic laboratory company, launched Gut Microbiome and HealthEx tests aimed at enhancing preventive healthcare by providing personalized health insights. Two specialized health tests focus on promoting preventive healthcare. The gut microbiome test analyzes gut health, offering insights into immune function, metabolism, and mental health. An advanced blood test evaluates DNA to assess potential health risks related to lifestyle, diet, and genetics. Both tests provide personalized recommendations to help individuals manage their well-being.What Are Latest Mergers And Acquisitions In The Microbiome Market?
In December 2023, L'Oréal S.A., a France-based cosmetics company, acquired Lactobio for an undisclosed amount. Through this acquisition, L'Oréal S.A. aims to strengthen expertise in microbiome science, enhancing its product offerings by incorporating innovative solutions based on probiotics. Lactobio is a Denmark-based biotechnology research company that leverages microbiome science to create novel health interventions.Regional Insights
North America was the largest region in the microbiome market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Microbiome Market?
The microbiome market consists of sales of firmicutes, bacteroidetes, and actinobacteria. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Microbiome Market Report 2026?
The microbiome market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the microbiome industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Microbiome Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $0.94 billion |
| Revenue Forecast In 2035 | $1.64 billion |
| Growth Rate | CAGR of 14.8% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Microbe Category, Product, Technology, End-Use |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Seres Therapeutics, Enterome Bioscience, Ferring Pharmaceuticals, Vedanta BioSciences, Second Genome Inc., Microbiotica, Rebiotix Inc, Locus Biosciences, Osel Inc., Xbiome Co. Ltd, Microba Life Sciences, Biome Australia, Shoreline Biome, BugSpeaks, Atlas Biomed, BiomX Ltd, ImmuneBiotech Medical Sweden AB, MetaboGen AB, Viome, PharmaBiome, NCCR Microbiomes, MaaT Pharma, Eligo Bioscience, T3 Pharmaceuticals, MicroBiome Therapeutics LLC, OpenBiome, Microbiome Insights Inc., Lallemand Health Solutions, Mybiotics Pharma, DayTwo, Next Biosciences, ViThera Pharmaceuticals Inc., Inqaba Biotechnical Industries (Pty), SNIPR Biome, MyBiome |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
